Abstract:BACKGROUND AND OBJECTIVE:Mesenchymal stem cells (MSCs), particularly bone MSCs (BMSCs) offer great potentials for targeted therapeutic applications owing to their migratory and differentiation capacities. Significant advances have been achieved in the differentiation of hepatocyte or hepatocyte-like cells both in vitro and in vivo. However, there is limited knowledge on the differentiation of BMSCs into bipotential hepatic progenitor cells or cholangiocyte. This study reviews the potentials and advances in using MSCs as vehicles for targeted drug delivery and proposes a new method for the induction of differentiation in rat BMSCs into hepatic progenitor cells in vitro and assesses the differential and migratory capacities.METHODS:The BMSCs of Sprague Dawley (SD) rats were harvested from the femur and the tibiae of the rats. After isolation and culturing, BMSCs from Passage 1 were used for the study. The in vitro differentiation of the hepatic progenitor cells was performed using a 2-step induction approach after 5-day serum deprivation from the BMSCs and culturing in Dulbecco's modified eagle medium. Spontaneous in vitro differentiation of BMSCs was examined in the absence of growth factors for 15 days as control treatment. Hepatocytes differentiation was achieved by exposing the culture to collagen type I-coated plates. Cholangiocytes differentiation was achieved with replating the BMC-HepPCs on a layer of Matrigel. Immunofluorescence was conducted on twelve-well plates to determine cell differentiations. Real-Time Quantitative Reverse Transcription PCR (qRTPCR) was used to determine the total RNA extracted using the Trizol LS reagent. In the hepatocyte differentiation group, after periodic acid-schiff (PAS) staining for glycogen, inverted microscope was used to determine differentiations and undifferentiated BMC-HepPCs served as controls. The amount of low-density lipoprotein (LDL) uptake by the BMSCs-derived hepatocytes was assessed using fluorescence microscopy. The secretion of rat albumin was quantified using a quantitative ELISA kit.RESULTS:Differentiation induction is indicative of the sequential supplementation of sodium butyrate and cytokines, which are involved in the embryonic development of the mammalian liver. Hepatic progenitor cells, derived from bone marrow, can be differentiated bidirectionally in vitro into both hepatocyte and cholangiocyte cell-lines. The differentiated cells, including hepatic progenitor cells, hepatocytes, and bile duct-like cells, were identified and analyzed at mRNA and protein levels.CONCLUSION:Our findings show that BMSCs can be utilized as novel bipotential hepatic progenitor cells and thereby for hepatobiliary disease treatment or hepatobiliary tissue-engineering.

Transdifferentiation of bone marrow mesenchymal stem cells into hepatocytes

Factors Influencing Stem Cell Differentiation into the Hepatic Lineage in Vitro

Committed-differentiation of Transplanted Bone Derived Mesenchymal Stem Cells and Their Potential to Amend Damaged Liver Functions: in Vivo Experiment with Mice

The Culture of Human Bone Marrow Mesenchymal Stem Cells

In VitroandIn VivoHepatic Differentiation of Adult Somatic Stem Cells and Extraembryonic Stem Cells for Treating End Stage Liver Diseases

Transdifferentiation of mouse BM cells into hepatocyte-like cells.

Differentiation of Adult Stem Cells into Hepatocytes

Multiple Dimensions of Using Mesenchymal Stem Cells for Treating Liver Diseases: from Bench to Beside.

Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease

Current understanding of adipose-derived mesenchymal stem cell-based therapies in liver diseases

Mesenchymal Stem Cells (mscs) in Targeted Drug Delivery: Literature Review and Exploratory Data on Migrating and Differentiation Capacities of Bone MSCs into Hepatic Progenitor Cells.

Bone Marrow Mesenchymal Stem Cells Exhibit a Transdifferentiation and Therapeutic Effects in a Murine Model of Orthotopic Hepatocellular Carcinoma.

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

In Vitro Differentiation of Mouse Bone Marrow Stromal Stem Cells into Hepatocytes Induced by Conditioned Culture Medium of Hepatocytes

Differentiation of Bone Marrow Derived Thy-1 + Β 2 M − Cells into Hepatocytes Induced by Coculture with Transgenic CFSCs

Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases

Current Status and Future Prospects of Mesenchymal Stem Cell Therapy for Liver Fibrosis

Using Bone Marrow Mesenchymal Stem Cells to Treat Liver Diseases

Differentiation of mouse bone marrow mesenchymal stem cells into hepatocyte-like cells in vitro

MOUSE BONE MARROW STEM CELLS DIFFERENTIATE INTO HEPATOCYTE-LIKE CELLS IN VITRO

Transcriptome Profiling Reveals Distinct Phenotype Of Human Bone Marrow Mesenchymal Stem Cell-Derived Hepatocyte-Like Cells